Servier agreed to acquire Edgewise Therapeutics’ muscular dystrophy business in a transaction valued at up to $2.65 billion, betting that neuromuscular franchise scale can accelerate its neurology ambitions. The centerpiece is sevasemten, a fast skeletal myosin inhibitor in studies across Becker muscular dystrophy and Duchenne muscular dystrophy. For Edgewise, the deal monetizes its muscular dystrophy platform and transfers development execution to a larger pharma with resources to fund pivotal readouts and expansion. For Servier, it adds an asset positioned for both rare disease markets and potential future development based on clinical progress. The transaction is structured with a large upfront payment and milestone-based contingent value, making timing of regulatory and commercial events central to the deal’s ultimate economics. Overall, the acquisition underlines how late-stage neuromuscular development assets continue to attract strategic interest as rare-disease pipelines mature.